Review of NICE Technology Appraisal Guidance No.221; Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura, and No.293; Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura

The planned date for review of the above guidance is March 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

No new evidence has been identified is expected to lead to a change in the existing recommendation and there is no data with which to directly compare the clinical effectiveness of romiplostim and eltrombopag. Therefore, it is proposed that both TA221 and TA293 should be moved to the static list.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

Alongside adding TA221 and TA293 to the static list, NICE intends to update the wording of the recommendations within TA221 to be in line with current NICE wording conventions and to support consistent implementation of the 2 pieces of guidance across England.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

March 2014